[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100530273":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":40,"responsibleParty":53,"collaborators":26,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":58,"sex":64,"minAge":65,"maxAge":26,"enrollmentInfo":66,"targetDuration":26,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":26,"overallStatus":42,"whyStopped":26,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Rijnstate Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention","ACTIVE_COMPARATOR","Semaglutide injections + combined lifestyle intervention",[13],"Drug: Semaglutide 3.2 MG\u002FML",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo Semaglutide injections + combined lifestyle intervention",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Semaglutide 3.2 MG\u002FML","Intervention arm receives semaglutide in addition to combined lifestyle intervention",[9],null,{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"Control arm receives placebo in addition to combined lifestyle intervention",[15],[31],{"name":32,"affiliation":5,"role":33},"Ron Pisters, dr.","PRINCIPAL_INVESTIGATOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":26,"email":39},"Leonard Voorhout, MSc","CONTACT","+31650818296","lvoorhout@rijnstate.nl",[41],{"facility":5,"status":42,"city":43,"state":44,"zip":26,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":26},"RECRUITING","Arnhem","Gelderland","Netherlands","NL",{"type":48,"coordinates":49},"Point",[50,51],5.91111,51.98,{"lat":51,"lon":50},{"type":33,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Ron Pisters","Head of Cardioresearch and principal investigator, dr. R. Pisters","100530273","phase-4-dutch-weight-control-in-atrial-fibrillation-study-100530273",false,"NCT06184633","DUTCH Weight Control in Atrial Fibrillation Study","DUTCH Weight Control in Atrial Fibrillation Study, a Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Trial","DUTCH-WAIST","Inclusion Criteria:\n\n* Symptomatic, first detected (at maximum 6 months prior to enrollment) persistent AF -\n* Age ≥ 18\n* Obesity, as defined as:\n\n  * BMI ≥ 30 kg\u002Fm2, or\n  * BMI ≥27 kg\u002Fm2 with the presence of at least one weight related comorbidity (treated or untreated, e.g. hypertension, dyslipidaemia, obstructive sleep apnea, cardiovascular disease)\n* Scheduled ECV\n* Written informed consent\n\nExclusion Criteria:\n\n* Permanent AF\n* Secondary AF, i.e. due to thyrotoxicosis, infection (e.g. pneumonia) or post-(cardiothoracic) surgery\n* Current or previous treatment with amiodaron\n* HbA1c ≥ 48 mmol\u002FL, \\\u003C3 months prior to randomization\n* History of diabetes mellitus type 1 or 2\n* Prior bariatric surgery\n* Use of other anti-obesity medication, \\\u003C3 months prior to enrollment\n* Contra-indication for, or prior use of a GLP1-receptor agonist\n* History of chronic pancreatitis or acute pancreatitis \\\u003C6 months\n* Acute coronary syndrome \\\u003C6 months\n* Severe (grade III) valvular disease\n* eGFR \\\u003C30 mL\u002Fmin\u002F1.73m2\n* Heart failure NYHA class III-IV\n* Participation in another investigational drug or device study in the past 30 days (registry enrollment is allowed)\n* Any condition or therapy, which would make the participant unsuitable for the study (e.g. vulnerable, non-compliance) or life-expectancy \\\u003C12 months, as judged by the treating physician.\n* Female who is pregnant, breastfeeding, intends to become pregnant, or is of child-bearing potential and not using a highly effective contraceptive method.","ALL","18 Years",{"count":67,"type":68},280,"ESTIMATED","INTERVENTIONAL",[71],"PHASE4","Quantify the effect of an innovative weight loss management on rhythm control.",[74,75,76],"Atrial Fibrillation","Obesity","Weight Loss","2024-09-09",{"date":79,"type":80},"2024-09-19","ACTUAL",{"date":82,"type":80},"2024-07-21",{"date":84,"type":68},"2027-05-01",{"name":5,"class":6},1]